Canopy Growth Corporation

NasdaqGS:CGC Stock Report

Market Cap: US$241.6m

Canopy Growth Valuation

Is CGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CGC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CGC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CGC?

Key metric: As CGC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CGC. This is calculated by dividing CGC's market cap by their current revenue.
What is CGC's PS Ratio?
PS Ratio1.3x
SalesCA$280.50m
Market CapCA$351.27m

Price to Sales Ratio vs Peers

How does CGC's PS Ratio compare to its peers?

The above table shows the PS ratio for CGC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
MDWD MediWound
10.7x37.0%US$211.3m
AQST Aquestive Therapeutics
4.7x30.5%US$275.4m
ZYBT Zhengye Biotechnology Holding
8.3xn/aUS$216.5m
PROC Procaps Group
0.4xn/aUS$179.5m
CGC Canopy Growth
1.3x7.1%US$351.3m

Price-To-Sales vs Peers: CGC is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (6x).

Price to Sales Ratio vs Industry

How does CGC's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

69 CompaniesPrice / SalesEstimated GrowthMarket Cap
VTRS Viatris
0.9x-1.3%US$13.46b
OGN Organon
0.6x0.5%US$4.11b
PRGO Perrigo
0.8x3.7%US$3.40b
BHC Bausch Health Companies
0.3x0.6%US$2.73b
CGC 1.3xIndustry Avg. 3.2xNo. of Companies69PS048121620+
69 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CGC is good value based on its Price-To-Sales Ratio (1.3x) compared to the US Pharmaceuticals industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is CGC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CGC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.3x
Fair PS Ratio1.8x

Price-To-Sales vs Fair Ratio: CGC is good value based on its Price-To-Sales Ratio (1.3x) compared to the estimated Fair Price-To-Sales Ratio (1.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CGC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.99
US$4.23
+112.4%
64.5%US$10.43US$0n/a10
Jan ’26US$2.74
US$4.30
+56.8%
63.6%US$10.48US$0n/a10
Dec ’25US$3.87
US$4.93
+27.4%
55.1%US$10.77US$0n/a11
Nov ’25US$4.86
US$5.81
+19.6%
55.8%US$13.34US$0n/a11
Oct ’25US$4.41
US$5.81
+31.8%
55.8%US$13.34US$0n/a11
Sep ’25US$5.21
US$6.31
+21.1%
47.8%US$13.10US$0n/a12
Aug ’25US$6.77
US$6.77
+0.05%
48.4%US$14.67US$0n/a12
Jul ’25US$6.39
US$6.46
+1.0%
51.1%US$14.62US$0n/a13
Jun ’25US$8.53
US$5.56
-34.8%
63.3%US$14.68US$0n/a12
May ’25US$11.44
US$5.61
-50.9%
77.1%US$18.17US$0n/a12
Apr ’25US$7.53
US$3.98
-47.2%
42.6%US$6.71US$0n/a12
Mar ’25US$3.21
US$3.98
+23.9%
42.6%US$6.71US$0n/a12
Feb ’25US$5.03
US$6.59
+31.1%
63.2%US$14.93US$0US$1.9912
Jan ’25US$5.11
US$7.12
+39.3%
59.2%US$15.14US$0US$2.7413
Dec ’24US$6.18
US$6.40
+3.5%
67.2%US$14.60US$0US$3.8714
Nov ’24US$5.53
US$7.51
+35.6%
79.2%US$21.63US$0US$4.8613
Oct ’24US$7.83
US$7.27
-7.1%
84.5%US$22.19US$0US$4.4113
Sep ’24US$5.50
US$6.37
+15.7%
92.3%US$22.17US$0US$5.2113
Aug ’24US$4.72
US$16.82
+256.6%
125.8%US$67.76US$0US$6.7713
Jul ’24US$3.88
US$16.60
+327.9%
123.3%US$67.91US$0US$6.3914
Jun ’24US$8.35
US$25.86
+209.8%
65.5%US$66.71US$7.41US$8.5314
May ’24US$12.90
US$26.50
+105.4%
61.4%US$66.44US$12.55US$11.4414
Apr ’24US$17.50
US$27.61
+57.8%
55.5%US$66.34US$12.90US$7.5316
Mar ’24US$22.50
US$27.76
+23.4%
54.8%US$66.30US$12.89US$3.2116
Feb ’24US$30.80
US$36.38
+18.1%
65.0%US$105.36US$15.80US$5.0316
Analyst Price Target
Consensus Narrative from 10 Analysts
US$4.22
Fair Value
52.8% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 02:46
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Canopy Growth Corporation is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Capital Markets
Gaurav JainBarclays